ARCpoint Inc
ARC
Minas Metals Ltd
MINA
Quri-Mayu Developments Ltd
QURI
KGL Resources Ltd
KGL.H
Alerio Gold Corp
ALE
CA Stock MarketDetailed Quotes
NGEN NervGen Pharma Corp
- 2.730
- +0.160+6.23%
15min DelayMarket Closed Dec 13 16:00 ET
191.94MMarket Cap-7.18P/E (TTM)
2.750High2.560Low88.03KVolume2.560Open2.570Pre Close234.58KTurnover3.98052wk High0.15%Turnover Ratio70.31MShares1.62052wk Low-0.38EPS TTM159.23MFloat Cap3.980Historical HighLossP/E (Static)58.33MShs Float0.800Historical Low-0.38EPS LYR7.39%Amplitude--Dividend TTM20.84P/B1Lot Size--Div YieldTTM
NervGen Pharma Corp Key Stats
Quarterly+Annual
YOY
| (Q3)Sep 30, 2024 | (Q2)Jun 30, 2024 | (Q1)Mar 31, 2024 | (FY)Dec 31, 2023 | (Q4)Dec 31, 2023 | (Q3)Sep 30, 2023 | (Q2)Jun 30, 2023 | (Q1)Mar 31, 2023 | (FY)Dec 31, 2022 | (Q4)Dec 31, 2022 | |
|---|---|---|---|---|---|---|---|---|---|---|
| Total revenue | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 |
| Operating revenue | --0 | --0 | --0 | --0 | --0 | --0 | --0 | --0 | --0 | --0 |
| Cost of revenue | ||||||||||
| Gross profit | ||||||||||
| Operating expense | 109.51%7.16M | 25.80%6M | 5.36%4.97M | -22.79%17.78M | -28.15%4.87M | -30.62%3.42M | -24.45%4.77M | -5.75%4.72M | 79.73%23.03M | 63.60%6.78M |
| Selling and administrative expenses | 9.33%2.79M | -31.83%2.2M | 18.12%1.97M | 51.96%9.63M | 29.91%2.18M | 48.98%2.55M | 108.99%3.23M | 19.20%1.67M | 6.75%6.34M | 4.10%1.68M |
| -General and administrative expense | 9.33%2.79M | -31.83%2.2M | 18.12%1.97M | 51.96%9.63M | 29.91%2.18M | 48.98%2.55M | 108.99%3.23M | 19.20%1.67M | 6.75%6.34M | 4.10%1.68M |
| Research and development costs | 421.08%4.36M | 150.19%3.8M | -1.65%2.97M | -51.57%8.05M | -47.48%2.67M | -73.71%837.57K | -68.00%1.52M | -16.11%3.02M | 141.77%16.61M | 100.60%5.08M |
| Depreciation amortization depletion | -97.19%703 | -95.60%1.08K | 0.17%24.36K | 34.36%98.57K | 1.47%24.67K | 2.89%25.02K | 3.26%24.56K | 2,467.69%24.32K | 3,471.81%73.37K | 3,057.92%24.32K |
| -Depreciation and amortization | -97.19%703 | -95.60%1.08K | 0.17%24.36K | 34.36%98.57K | 1.47%24.67K | 2.89%25.02K | 3.26%24.56K | 2,467.69%24.32K | 3,471.81%73.37K | 3,057.92%24.32K |
| Operating profit | -109.51%-7.16M | -25.80%-6M | -5.36%-4.97M | 22.79%-17.78M | 28.15%-4.87M | 30.62%-3.42M | 24.45%-4.77M | 5.75%-4.72M | -79.73%-23.03M | -63.60%-6.78M |
| Net non-operating interest income (expenses) | 78.45%243.68K | 111.24%294.88K | -32.00%102.95K | 275.63%550.07K | 42.47%122.55K | 130.34%136.55K | 316.28%139.59K | 773.19%151.39K | -1,164.70%-313.2K | 569.88%86.01K |
| Non-operating interest income | 78.45%243.68K | 111.24%294.88K | -32.00%102.95K | 173.13%550.07K | 42.47%122.55K | 111.67%136.55K | 316.28%139.59K | 773.19%151.39K | 584.62%201.4K | 569.88%86.01K |
| Non-operating interest expense | ---- | ---- | ---- | --0 | ---- | ---- | ---- | ---- | --514.6K | --0 |
| Other net income (expenses) | 264.86%1.69M | -1,504.97%-2.12M | 1,853.67%2.52M | -297.08%-5.16M | -608.91%-3.86M | -154.49%-1.02M | -238.73%-132.12K | -840.57%-143.77K | 4,636.56%2.62M | 5,889.78%757.77K |
| Gain on sale of security | 264.86%1.69M | -1,504.97%-2.12M | 1,853.67%2.52M | -297.08%-5.16M | -608.91%-3.86M | -154.49%-1.02M | -238.73%-132.12K | -840.57%-143.77K | 4,636.56%2.62M | 5,889.78%757.77K |
| Income before tax | -21.46%-5.23M | -64.34%-7.83M | 50.19%-2.35M | -8.01%-22.38M | -44.92%-8.61M | -23.07%-4.3M | 24.63%-4.76M | 5.20%-4.71M | -62.83%-20.72M | -43.25%-5.94M |
| Income tax | ||||||||||
| Earnings from equity interest net of tax | ||||||||||
| Net income | -21.46%-5.23M | -64.34%-7.83M | 50.19%-2.35M | -8.01%-22.38M | -44.92%-8.61M | -23.07%-4.3M | 24.63%-4.76M | 5.20%-4.71M | -62.83%-20.72M | -43.25%-5.94M |
| Net income continuous operations | -21.46%-5.23M | -64.34%-7.83M | 50.19%-2.35M | -8.01%-22.38M | -44.92%-8.61M | -23.07%-4.3M | 24.63%-4.76M | 5.20%-4.71M | -62.83%-20.72M | -43.25%-5.94M |
| Noncontrolling interests | ||||||||||
| Net income attributable to the company | -21.46%-5.23M | -64.34%-7.83M | 50.19%-2.35M | -8.01%-22.38M | -44.92%-8.61M | -23.07%-4.3M | 24.63%-4.76M | 5.20%-4.71M | -62.83%-20.72M | -43.25%-5.94M |
| Preferred stock dividends | ||||||||||
| Other under preferred stock dividend | ||||||||||
| Net income attributable to common stockholders | -21.46%-5.23M | -64.34%-7.83M | 50.19%-2.35M | -8.01%-22.38M | -44.92%-8.61M | -23.07%-4.3M | 24.63%-4.76M | 5.20%-4.71M | -62.83%-20.72M | -43.25%-5.94M |
| Diluted earnings per share | 0.00%-0.07 | -37.50%-0.11 | 50.00%-0.04 | 2.56%-0.38 | -50.00%-0.15 | -16.67%-0.07 | 38.46%-0.08 | 27.27%-0.08 | -21.88%-0.39 | -11.11%-0.1 |
| Basic earnings per share | 0.00%-0.07 | -37.50%-0.11 | 50.00%-0.04 | 2.56%-0.38 | -50.00%-0.15 | -16.67%-0.07 | 38.46%-0.08 | 27.27%-0.08 | -21.88%-0.39 | -11.11%-0.1 |
| Dividend per share | ||||||||||
| Accounting Standards | US-GAAP | US-GAAP | US-GAAP | US-GAAP | US-GAAP | US-GAAP | US-GAAP | US-GAAP | US-GAAP | US-GAAP |
| Audit Opinions | -- | -- | -- | Unqualified Opinion | -- | -- | -- | -- | Unqualified Opinion | -- |
FY: Financial Year. Refers to the 10-K file disclosed by the listed company to the SEC.
Q: Quarter. Refers to the 10-Q file disclosed by the listed company to the SEC. Q1, Q2, Q3, and Q4 are quarterly reports each with a span of 3 months; Q6 and Q9 are cumulative reports, with Q6 including 6 months and Q9 9 months.